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Introduction
Human papillomaviruses (HPV) comprise a double-stranded DNA genome of 45 approximately 8 kb which is replicated via host cell polymerases with an error rate of ca. 46 2x10 -8 base substitutions, per site, per year (1), substantially lower than that found in the 47 induced by natural infection protect against subsequent reinfection by the same HPV 66 genotype but increasing evidence indicates that high antibody titers can be associated 67 with a reduced risk of reinfection (12) (13) (14) (15) . cross-protection has also been demonstrated against closely-related genotypes, 74 particular HPV31, . HPV vaccine type-specific protection is 75 assumed to be mediated by L1 neutralizing antibodies which can be detected in the 76 serum and cervicovaginal secretions of vaccinees (16, (19) (20) (21) (22) . The role of L1 77 neutralizing antibodies in mediating cross-protection is less clear although a recent 78 study reported an association between the presence of HPV31 cross-neutralizing 79 antibodies and a reduced risk of HPV31 infection (23). Next generation L1 VLP-based 80 vaccines aim to extend the breadth of coverage by incorporating an increased number 81 of L1 VLP (24, 25) .
83
Intra-genotype variation within the L1 protein is generally localized to the surface-84 exposed loop domains (26), akin to the majority of inter-genotype variation (27, 28) . 85 Data informing the potential impact of such variation on L1 antigenicity are limited to 86 HPV16 where L1L2 pseudoviruses (PsV) representing lineage-specific L1 variants were 87 neutralized to a similar extent by antibodies elicited against a single L1 VLP (29) . 88 However, the impact of a common Thr to Ala switch at amino acid residue position 266 89 within the FG loop of HPV16 was not evaluated, nor was variation within the 90 corresponding L2. Another study found that an FG loop specific neutralizing monoclonal 91 antibody (MAb), H16.E70, had reduced recognition for HPV16 L1 VLP bearing a Thr at 92 amino acid residue 266 indicating that variation within this region can impact upon 93 antigenicity (30). 94 95 HPV31 is closely related to HPV16 within the Alpha-9 species group and is associated 96 with ca. 3.8% of cervical cancer cases worldwide (31). The full genome sequence 97 analysis of HPV31 has led to the delineation of three distinct variant lineages: A, B and 98 C (4). Infections due to HPV31 lineage variants A or B have been associated with an 99 increased risk of developing cervical intraepithelial neoplasia grades 2-3 (CIN2/3) yet 100 somewhat paradoxically infections with lineage variant C appear to persist for longer 101 (32, 33) . Differences in the natural history between variants of other HPV genotypes 102 have also been observed (34, 35) . The relative infectivity of variants or the ability of 103 variants to differentially disrupt cellular differentiation are possible virological factors 104 which can contribute to the disparities in variant pathology (3). One study suggested 105 that the genetic background of the host may also play a role since African-American 106 women were found to be less likely to clear a HPV31 lineage variant C infection than a 107 lineage variant A infection, yet there was no difference in the likelihood of clearing 108 lineage variant A over C in Caucasian women (33). software (DNASTAR, Inc). The HPV31 L1 and L2 sequences generated in this study 140 were assigned the following GenBank accession numbers: KJ754561 -KJ754580.
141
Additional HPV31 L1 and L2 sequences were downloaded from the National Center for 142 Biotechnology Information [NCBI: http://www.ncbi.nlm.nih.gov/, accession numbers: 143 HQ537666 -HQ537687 (4), U37410 (41) and J04353 (42)] and analyzed using the The PsV neutralization assay was performed as previously described (48) (Figure 2A) . All three lineage variant PsV, herein referred to as HPV31 A PsV, HPV31 234 B PsV and HPV31 C PsV, generated similar sized PsV particles of around 50nm and 235 produced comparable PI ratios of ca. 10 2 (Figure 2B) . The PsV preparations also 236 contained L2 protein and luciferase reporter plasmid (data not shown).
238
The HPV31 variant PsV were tested against sera from girls who received either the 239 Cervarix® or Gardasil® (n=46) HPV vaccine ( Table 1) (Figure 2C) .
261
The three variant PsV demonstrated differential susceptibility to neutralization by HPV31 262 VLP mouse polyclonal serum (Figure 3) . Both HPV31 B PsV (median log 10 263 neutralization titer, 4.27; IQR, 3.75 -4.55) (Wilcoxon paired signed rank test p = 0.008) 264 and HPV31 C PsV (4.18; 3.86 -4.49) (p = 0.007) were more sensitive to neutralization 265 by HPV31 A VLP sera compared to the homologous HPV31 A PsV (4.09; 3.54 -4.26). 
285
Although the cross-reactive MAbs (31.D24, 31.B5, 31.C19 and 31.E22) bound the L1 286 VLP they did not bind or neutralize the L1L2 PsV ( Table 3) . All type-specific MAbs were 287 able to neutralize the three variant PsV to similar orders of magnitude (Table 3) . Table 3) . Figure 4A ). The FG loop of monomer 1 (FG 1 ) is adjacent to 295 the BC 5 , DE 1, DE 5 , EF 1, HI 4 and HI 5 loops within the capsomer ( Figure 4B ) and residues 296 267 and 274 are within close proximity (within 10Å) to residue positions predominantly 297 within the adjacent BC 5 , FG 1 ,and HI 5 loops ( Figure 4C and 4D) . These include Lysine This study attempted to evaluate the potential impact of non-synonymous SNP within 301 the HPV31 L1 and L2 genes on capsid protein antigenicity and immunogenicity. We with ≤4-fold difference in neutralization titer between the homologous and heterologous 366 types, leading to the conclusion that HPV16 variants belong to a single serotype (29).
368
The criterion used to designate serotypes is generally based upon an fold difference in 369 antibody-mediated neutralization titers between viral types, which differ in magnitude 370 and range between virus families: Adenovirus 8-to 16-fold (52), Rotavirus ≥20-fold (53),
371
Polyomavirus 4-to 100-fold (54). For HPV there are no currently defined criteria with 372 which to designate L1 serotypes. It is reasonably clear that HPV genotypes induce high 373 titer, type-specific neutralizing antibody responses which represent different serotypes 374 (55-57). However, for lineage variants the relationship between L1 sequence and 375 antigenicity is less clear (29, 58) . There are potential shortcomings to this work. L1 VLP immunizations were carried out 391 using a relative small number of animals and while all three constructs induced 392 neutralizing antibodies against all three variant PsV, the variability inherent in using 393 small groups of animals may have concealed subtle differences in immunogenicity.
394
Although HPV L1L2 PsV have been used widely to monitor antibody responses to 395 vaccine and natural infection (22, 47, 48, 60) , as well as elucidate steps in the entry 396 process (61-64), there are likely to be some differences between how these behave in 
